First nasal spray for treating adult Covid patients launched in India
First nasal spray for treating adult Covid patients launched in India

First nasal spray for treating adult Covid patients launched in India

Mumbai based innovation-driven global pharma company Glenmark has launched Nitric Oxide Nasal Spray (FabiSpray) in India, in partnership with SaNOtize, for treatment of adult patients suffering from COVID-19.

Glenmark received manufacturing and marketing approval from India’s drug regulator, Drugs Controller General of India, for Nitric Oxide Nasal Spray as part of the accelerated approval process.

“Phase 3 trial in India met the key endpoints and demonstrated reduction of viral load of 94 per cent in 24 hours and 99 per cent in 48 hours. Nitric Oxide Nasal Spray (NONS) was safe and well-tolerated in COVID-19 patients. Glenmark to market NONS under the brand name FabiSpray,” reads the official statement.

The company claims that when the Nitric Oxide Nasal is sprayed over nasal mucosa it acts as a physical and chemical barrier against the virus. “FabiSpray is designed to kill the COVID-19 virus in the upper airways. It has proven anti-microbial properties with a direct virucidal effect on SARS-CoV-2. NONS when sprayed over nasal mucosa acts as a physical and chemical barrier against the virus, preventing it from incubating and spreading to the lungs,” the statement reads.

यह भी पढ़ें:   Amit Shah to introduce 'The Criminal Procedure (Identification) Bill, 2022' in LS today

Terming the spray an effective and safe antiviral treatment for COVID-19, Glenmark Pharmaceuticals Ltd’s Chief Commercial Officer Robert Crockart said “we are confident it will offer patients a much needed and timely therapy option.” — ANI